-
公开(公告)号：US20210401940A1
公开(公告)日：2021-12-30
申请号：US17371646
申请日：2021-07-09
IPC分类号： A61K38/20 , A61K45/06 , A61K31/436 , G01N33/564 , G01N33/68
摘要： The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
62.发明申请公开(公告)号：US20210338773A1
公开(公告)日：2021-11-04
申请号：US17282502
申请日：2018-10-17
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , SORBONNE UNIVERSITE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -
摘要： The present invention relates to a new method for treating a patient suffering from a retinal degenerative disease. The Inventors discovered that nucleolin (NCL) is responsible in rods of the production of the short messenger of NXNL1 gene encoding RdCVF, a crucial factor for cones survival. Thus, the administration of NCL into the retina or the overexpression of NCL in recombinant cones to be transplanted into the retina, leads to a RdCVF expression and secretion by the cones themselves in order to encourage their own survival in an autocrine manner through the BSG1/GLUT1 complex. Thus, the invention concerns nucleolin polynucleotide or polypeptide for use in the treatment of a retinal degenerative disease in a patient in need. The invention also relates to recombinant cone overexpressing NCL for use in the treatment of a retinal degenerative disease.
-
公开(公告)号：US20210324049A1
公开(公告)日：2021-10-21
申请号：US17258891
申请日：2019-07-09
申请人： INSERM (Institut National de La Santé et de la Recherche Médicale) , Institut Pasteur de Lille , Centre National de la Recherche Scientifique (CNRS) , Université de Lille
IPC分类号： C07K16/10 , G01N33/576 , G01N33/535
摘要： Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a non-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 542 to 555 of SEQ ID NO: 1.
-
公开(公告)号：US11142548B2
公开(公告)日：2021-10-12
申请号：US16300438
申请日：2017-05-10
申请人： SORBONNE UNIVERSITE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
摘要： Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.
-
公开(公告)号：US20210299195A1
公开(公告)日：2021-09-30
申请号：US16759591
申请日：2018-10-28
申请人： Sorbonne Universite , INSERM (Institut National de la Santé et de la Recherche Médicale) , Assistance Publique - Hôpitaux de Paris
发明人： Bertrand Bellier , David Klatzmann
IPC分类号： A61K35/76 , C07K14/705 , C07K14/005 , C12N7/00 , A61P37/08
摘要： The invention relates to a virus-like particle comprising an allergen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an allergy.
-
公开(公告)号：US20210290595A1
公开(公告)日：2021-09-23
申请号：US17200146
申请日：2021-03-12
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Nice Sophia Antipolis , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： A61K31/415 , A61P3/10 , C12N15/113
摘要： The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin. Accordingly, the present invention relates to a method of treating hyperglycemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of Gfi1.
-
67.发明申请公开(公告)号：US20210238605A1
公开(公告)日：2021-08-05
申请号：US16972152
申请日：2019-06-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PAUL SABATIER TOULOUSE III , UNIVERSITY COLLEGE LONDON , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE , UNIVERSITÉ DE CAEN NORMANDIE , CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE CAEN
发明人： Marie-Pierre GRATACAP , Jean DARCOURT , Bart VANHAESEBROECK , Gaëtan CHICANNE , Bernard PAYRASTRE , Vincent LARRUE , Romain SOLINHAC , Aude JAFFRE , Denis VIVIEN , Typhaine ANQUETIL
IPC分类号： C12N15/113 , A61P9/10 , G01N33/50
摘要： Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an pot ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For NI instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (UR) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.
-
公开(公告)号：US11072661B2
公开(公告)日：2021-07-27
申请号：US16066015
申请日：2016-12-23
申请人： SORBONNE UNIVERSITE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSERM (Institut National de la Santé et de la Recherche Médicale)
摘要： Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.
-
公开(公告)号：US11052131B2
公开(公告)日：2021-07-06
申请号：US16339931
申请日：2017-10-04
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , UNIVERSITE DE BORDEAUX , INSTITUT BERGONIÉ
IPC分类号： A61K38/22 , A61P35/00 , C07K14/575
摘要： Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.
-
公开(公告)号：US20210189346A1
公开(公告)日：2021-06-24
申请号：US17055691
申请日：2019-05-16
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE RENNES 1 , ÉCOLE DES HAUTES ÉTUDES EN SANTÉ PUBLIQUE (EHESP)
发明人： Georges BAFFET , Sophie LANGOUET , Frédéric EZAN , Sophie ROSE , Marie CUVELLIER
摘要： A method of culturing animal cells, preferably primary hepatocytes, including a first step of culturing the animal cells in non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel, a second step of embedding the animal cells in a collagen matrix or in a gelatin matrix, and a third step of culturing the animal cells embedded in the collagen matrix or in the gelatin matrix, thereby obtaining 3D animal cell structures including proliferative animal cells, preferably spheroids including proliferative primary hepatocytes. Also, a spheroid including proliferative primary hepatocytes and the uses thereof for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the liver toxicity, genotoxicity and/or the effects of a drug or a compound.
-
-
-
-
-
-
-
-
-
搜索结果
846 条记录 (耗时 0.038 秒)
